Belgian biopharmaceutical company UCB has partnered with Harvard University researchers to study the species found in the human microbiome -- the bacteria living inside the human body -- and how they affect the body's immune system. The objective of the UCB-funded project is to discover new drugs for preventing or treating immunological disorders. "We hope this project will fundamentally shift the paradigm of drug development for immunological diseases, exploiting naturally occurring molecules evolutionarily designed to thwart or harness the immune system," Harvard researchers said.
UCB and Harvard unite to study the human microbiome
SmartBrief Job Listings for Education
|School District of Philadelphia - Director, Observation and Feedback Coaches Program||
School District of Philadelphia
|Opportunities for Former Teachers and Administrators with PLC Experience||
Learning Sciences International
|Instructional Designer, ESL||
Imagine Learning, Inc.
|Account Executive, National Accounts||